Updated:
Skyviews Life Science
Skyviews Life Science is a privately held advisory company specialised in precision health and longevity. It identifies investment opportunities in companies...
Skyviews Life Science
Skyviews Life Science is a privately held advisory company specialised in precision health and longevity. It identifies investment opportunities in companies at the growing interface between biotechnology, advanced nutrition and digital health. It targets private and public companies with better drugs, advanced technology platforms, preventive strategies, personalized solutions and more natural foods that will improve people's quality of life.
General information
Firm type
Generalist
Year founded
2018
Location
Region
Europe
Country
Switzerland
City
Grandvaux
Corporate office
Grandvaux, Switzerland
Principals
Dr. Stefan Catsicas
Co-Founder and Managing Partner
Dr. Irène Corthésy Malnoë
Partner and Senior Consultant
Sector focus
Frequently asked questions
How does Skyviews Life Science source proprietary deal flow?
Sourcing relies heavily on the academic and corporate networks of its founders. Stefan Catsicas serves on the board of Singapore's A*STAR, giving the firm visibility into early-stage research emerging from that government agency's labs. The firm's membership in the Swiss Biotech Association provides additional proximity to European life-science startups.
Does Skyviews participate in fund commitments or only direct deals?
Publicly available information describes Skyviews as identifying investment opportunities in private and public companies directly, with no mention of participating as a limited partner in external funds. Its advisory relationship with Precision Health Corporation points primarily toward direct company investments.
What investment stages does Skyviews Life Science typically target?
The firm concentrates on early-stage opportunities, spanning seed and startup phases. Its strategy page frames its focus around companies developing "better drugs, advanced technology platforms, preventive strategies, personalized solutions and more natural foods," hallmarks of capital-intensive early-stage life-science ventures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: